John W McEvoy1, Michael J Blaha1, Andrew P DeFilippis1, Joao A C Lima1, David A Bluemke1, W Gregory Hundley1, James K Min1, Leslee J Shaw1, Donald M Lloyd-Jones1, R Graham Barr1, Matthew J Budoff1, Roger S Blumenthal1, Khurram Nasir2. 1. From the Ciccarone Center for the Prevention of Heart Disease (J.W.M., M.J. Blaha, A.P.D., R.S.B., K.N.) and Division of Cardiology (J.A.C.L.), Johns Hopkins University, Baltimore, MD; Division of Cardiology, Rudd Heart and Lung Center, University of Louisville, KY (A.P.D.); Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD (D.A.B.); Division of Cardiology, Wake Forest University Health Center, Winston-Salem, NC (W.G.H.); Division of Cardiology, Cedars Sinai Medical Center, Heart Institute, Los Angeles, CA (J.K.M.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (L.J.S.); Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (D.M.L.-J.); Division of General Medicine, Division of Pulmonary, Allergy and Critical Care, Department of Medicine and Department of Epidemiology, Columbia University Medical Center, New York, NY (R.G.B.); Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.J. Budoff); Center for Wellness and Prevention, and Miami Cardiovascular Institute (MCVI), Baptist Health South Florida, Miami (K.N.); and Department of Medicine, Herbert Wertheim College of Medicine, and Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami (K.N.). 2. From the Ciccarone Center for the Prevention of Heart Disease (J.W.M., M.J. Blaha, A.P.D., R.S.B., K.N.) and Division of Cardiology (J.A.C.L.), Johns Hopkins University, Baltimore, MD; Division of Cardiology, Rudd Heart and Lung Center, University of Louisville, KY (A.P.D.); Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD (D.A.B.); Division of Cardiology, Wake Forest University Health Center, Winston-Salem, NC (W.G.H.); Division of Cardiology, Cedars Sinai Medical Center, Heart Institute, Los Angeles, CA (J.K.M.); Division of Cardiology, Emory University School of Medicine, Atlanta, GA (L.J.S.); Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (D.M.L.-J.); Division of General Medicine, Division of Pulmonary, Allergy and Critical Care, Department of Medicine and Department of Epidemiology, Columbia University Medical Center, New York, NY (R.G.B.); Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.J. Budoff); Center for Wellness and Prevention, and Miami Cardiovascular Institute (MCVI), Baptist Health South Florida, Miami (K.N.); and Department of Medicine, Herbert Wertheim College of Medicine, and Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami (K.N.). khurramn@baptisthealth.net.
Abstract
OBJECTIVES: To examine the contemporary effect of smoking in a multiethnic sample, and to explore the respective contributions of inflammation and subclinical atherosclerosis to the cardiovascular consequences of smoking. APPROACH AND RESULTS: We studied 6814 participants free of cardiovascular disease and coronary heart disease (CHD) from the Multiethnic Study of Atherosclerosis. Smoking status and cumulative exposure were determined by self-report and confirmed by urinary cotinine. Multivariable Cox regression was used to estimate the association between smoking parameters and all-cause cardiovascular disease, all-cause CHD, and hard CHD events. We further adjusted for high-sensitivity C-reactive protein and coronary artery calcium (CAC) in hierarchical Cox models. We identified 3218 never smokers, 2607 former smokers, and 971 current smokers. Median follow-up was 10.2 years. Compared with never smokers, adjusted hazard ratios in current smokers were 1.7 (95% confidence interval, 1.3-2.2) for all-cause cardiovascular disease, 1.6 (1.1-2.1) for all-cause CHD, and 1.7 (1.2-2.4) for hard CHD. Similarly, among current smokers, hazard ratios were higher in the 4th versus 1st quartile of pack-years (eg, all-cause CHD hazard ratio=2.7 [1.1-6.6]). Both CAC>100 and high-sensitivity C-reactive protein ≥3 mg/L identified higher relative risk among current smokers (eg, all-cause CHD hazard ratio of 3.0 [1.5-6.0, compared with CAC=0] and 2.6 [1.4-4.8, compared with high-sensitivity C-reactive protein <2 mg/L], respectively). However, CAC was a stronger mediator of events and adversely modified the effect of smoking on events (eg, P-interaction=0.02 for hard CHD). Compared with never smokers, former smokers (median cessation interval=22 years) had similar adjusted hazard for events. CONCLUSIONS: In this multiethnic cohort, current smoking and cumulative exposure remain important modifiable determinants of cardiovascular disease. Both high-sensitivity C-reactive protein ≥3 mg/L and, particularly, CAC>100 identified high-risk smokers who may benefit from more intensive smoking-cessation efforts.
OBJECTIVES: To examine the contemporary effect of smoking in a multiethnic sample, and to explore the respective contributions of inflammation and subclinical atherosclerosis to the cardiovascular consequences of smoking. APPROACH AND RESULTS: We studied 6814 participants free of cardiovascular disease and coronary heart disease (CHD) from the Multiethnic Study of Atherosclerosis. Smoking status and cumulative exposure were determined by self-report and confirmed by urinary cotinine. Multivariable Cox regression was used to estimate the association between smoking parameters and all-cause cardiovascular disease, all-cause CHD, and hard CHD events. We further adjusted for high-sensitivity C-reactive protein and coronary artery calcium (CAC) in hierarchical Cox models. We identified 3218 never smokers, 2607 former smokers, and 971 current smokers. Median follow-up was 10.2 years. Compared with never smokers, adjusted hazard ratios in current smokers were 1.7 (95% confidence interval, 1.3-2.2) for all-cause cardiovascular disease, 1.6 (1.1-2.1) for all-cause CHD, and 1.7 (1.2-2.4) for hard CHD. Similarly, among current smokers, hazard ratios were higher in the 4th versus 1st quartile of pack-years (eg, all-cause CHD hazard ratio=2.7 [1.1-6.6]). Both CAC>100 and high-sensitivity C-reactive protein ≥3 mg/L identified higher relative risk among current smokers (eg, all-cause CHD hazard ratio of 3.0 [1.5-6.0, compared with CAC=0] and 2.6 [1.4-4.8, compared with high-sensitivity C-reactive protein <2 mg/L], respectively). However, CAC was a stronger mediator of events and adversely modified the effect of smoking on events (eg, P-interaction=0.02 for hard CHD). Compared with never smokers, former smokers (median cessation interval=22 years) had similar adjusted hazard for events. CONCLUSIONS: In this multiethnic cohort, current smoking and cumulative exposure remain important modifiable determinants of cardiovascular disease. Both high-sensitivity C-reactive protein ≥3 mg/L and, particularly, CAC>100 identified high-risk smokers who may benefit from more intensive smoking-cessation efforts.
Authors: Xueqian Xie; Yingru Zhao; Geertruida H de Bock; Pim A de Jong; Willem P Mali; Matthijs Oudkerk; Rozemarijn Vliegenthart Journal: Circ Cardiovasc Imaging Date: 2013-06-11 Impact factor: 7.792
Authors: Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri Journal: N Engl J Med Date: 2013-07-18 Impact factor: 91.245
Authors: Megan Watson; Zeina Dardari; Sina Kianoush; Michael E Hall; Andrew P DeFilippis; Rachel J Keith; Emelia J Benjamin; Carlos J Rodriguez; Aruni Bhatnagar; Joao A Lima; Javed Butler; Michael J Blaha; Mahmoud Al Rifai Journal: Am J Cardiol Date: 2019-03-18 Impact factor: 2.778
Authors: Allen R Yu; Bima Hasjim; Luke E Yu; Christopher Gabriel; Alexander Anshus; Jonathan B Lee; Michael J Louthan; Esther C Kim; Katrina Lee; Christina Tse; Thomas Keown; Shadi Lahham; Maili Alvarado; Steven Bunch; Abdulatif Gari; J Christian Fox Journal: World J Emerg Med Date: 2017
Authors: Robin Nance; Joseph Delaney; John W McEvoy; Michael J Blaha; Gregory L Burke; Ana Navas-Acien; Joel D Kaufman; Elizabeth C Oelsner; Robyn L McClelland Journal: J Clin Epidemiol Date: 2016-10-18 Impact factor: 6.437
Authors: Mahmoud Al Rifai; Andrew P DeFilippis; John W McEvoy; Michael E Hall; Ana Navas Acien; Miranda R Jones; Rachel Keith; Hoda S Magid; Carlos J Rodriguez; Graham R Barr; Emelia J Benjamin; Rose Marie Robertson; Aruni Bhatnagar; Michael J Blaha Journal: Atherosclerosis Date: 2017-01-19 Impact factor: 5.162
Authors: Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-01 Impact factor: 4.733
Authors: John S Gottdiener; Petra Buzkova; Peter A Kahn; Christopher DeFilippi; Sanjiv Shah; Eddy Barasch; Jorge R Kizer; Bruce Psaty; Julius M Gardin Journal: Am J Cardiol Date: 2022-01-16 Impact factor: 2.778
Authors: Mahmoud Al Rifai; Michael J Blaha; Vijay Nambi; Steven J C Shea; Erin D Michos; Roger S Blumenthal; Christie M Ballantyne; Moyses Szklo; Philip Greenland; Michael D Miedema; Khurram Nasir; Jerome I Rotter; Xiuqing Guo; Jie Yao; Wendy S Post; Salim S Virani Journal: Circulation Date: 2021-12-08 Impact factor: 29.690